CD47-SIRPα Innate Immune Checkpoint on Neutrophils: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Leonie M. Behrens
,
Timo K. van den Berg
,
Marjolein van Egmond

Immunotherapy aims to engage various immune cells in the elimination of cancer cells. Neutrophils are the most abundant leukocytes in the circulation and have unique mechanisms by which they can kill cancer cells opsonized by antibodies. However, neutrophil effector functions are limited by the inhibitory receptor SIRPα, when it interacts with CD47. The CD47 protein is expressed on all cells in the body and acts as a ‘don’t eat me’ signal to prevent tissue damage. Cancer cells can express high levels of CD47 to circumvent tumor elimination. Thus, blocking the interaction between CD47 and SIRPα may enhance anti-tumor effects by neutrophils in the presence of tumor-targeting monoclonal antibodies. Blocking the CD47-SIRPα interaction may therefore potentiate neutrophil-mediated antibody-dependent cellular cytotoxicity (ADCC) towards cancer cells, and various inhibitors of the CD47-SIRPα axis are now in clinical studies.

  • tumor
  • antibody therapy
  • neutrophil
  • CD47-SIRPα
  • immune checkpoint

1. CD47-SIRPα as an Innate Immune Checkpoint in Neutrophil-Mediated Tumor Killing

The SIRP family is a multigene family consisting of five members: SIRPα, SIRPβ1, SIRPβ2, SIRPγ and SIRPδ in humans[1]. SIRPα (also known as CD172a, SHPS-1, p84, MFR, MYD-1 or PTPNS1) is an inhibitory receptor expressed on myeloid cells, including macrophages, neutrophils and myeloid dendritic cells, as well as on neuronal cells in the central nervous system[2]. The protein contains three extracellular immunoglobulin (Ig) superfamily (IgSF) domains, consisting of one V-type IgSF (IgV) domain and two C1-type IgSF (IgC) domains, one transmembrane region and an intracellular tail capable of inhibitory signaling (Figure 1)[3]. The intracellular tail contains four tyrosine residues, forming two typical immunoreceptor tyrosine-based inhibitory motifs (ITIM). In addition, the extracellular IgV-domain contains a ligand-binding region, allowing SIRPα to interact with its ligand, CD47[4].
Figure 1. The CD47-SIRPα axis. Interaction between the IgV-domain of CD47 and the IgV-domain of SIRPα results in phosphorylation of the two ITIMs in the intracellular SIRPα tail. As a consequence, the phosphatases SHP-1 and SHP-2 are recruited, which are subsequently activated and able to regulate downstream cellular signaling pathways, e.g., FcR or TLR signaling, by tyrosine dephosphorylation of various mediators. In addition, neutrophil Mac-1 activation is inhibited in a Kindlin3-dependent manner. Abbreviations: K3: Kindlin3. Created with Biorender.com.
The CD47 protein (also known as IAP, MER6 or OA3) is a transmembrane glycoprotein expressed on virtually all cells in the body, including both hematopoietic and non-hematopoietic cells[5]. It is a member of the Ig superfamily, and consists of an extracellular IgV-like domain at the N-terminus, a region with five membrane-spanning segments, and a cytoplasmic C-terminus ranging from 3–36 amino acids[6]. CD47 was identified independently on different cell types, resulting in different nomenclature. It was first described as integrin-associated protein (IAP), as it was shown to associate with integrins, e.g., αvβ3, on various cell types[7]. In addition, CD47 was identified as OA3, an antigen overexpressed on ovarian carcinoma cells[8]. As it is now clear that this molecule is expressed on various cell types, and can interact with different proteins, including integrins, thrombospondins (TSP), VEGFR and SIRPs, the current consensus is to refer to it as CD47[6][9].
The interaction between CD47 and SIRPα was first described in 1999 in mice[10]. Using SIRPα-expressing murine brain cells, CD47 was identified as a binding partner of SIRPα. This was confirmed by anti-CD47 mAbs, which blocked the attachment of various cells to SIRPα-coated substrates[10]. Subsequently, CD47 was also recognized as a ligand for SIRPα in humans[11]. Similarly, in rats a CD47-targeting mAb was identified to prevent the adherence of SIRPα-coated beads[12]. The interaction between CD47 and SIRPα has been analyzed in detail with high-resolution X-ray crystallography and mutagenesis studies[13]. The N-terminal end of SIRPα domain 1 (IgV-domain) consists of four loops, which all contribute to binding of CD47. The N-terminal end of CD47 also forms loops, which are needed for the interaction between CD47 and SIRPα. In addition, CD47 contains a pyroglutamate at the N-terminal, that plays a significant role in the interaction[13][14].
In humans, two allelic variants of SIRPα have been identified: SIRPα1 and SIRPαBIT[15]. Within a healthy Caucasian population, SIRPαBIT and SIRPα1 homozygotes represent 15.9 and 48.7% of the population, respectively, with 35.4% heterozygous for SIRPα1/SIRPαBIT[15]. These variants differ by as much as 13 amino acid residues in the IgV domain responsible for CD47 binding. However, no differences in CD47 binding were observed between SIRPα1 and SIRPαBIT[15][16][17]. This may not be surprising, as the polymorphisms occur primarily outside the CD47 binding site[15]. Whereas these polymorphisms could in principle still have an effect on downstream signaling capacities and thereby affect neutrophil effector functions, such as ADCC, no differences were observed in neutrophil-mediated ADCC of trastuzumab-coated SKBR3 cancer cells between neutrophils from donors with the three different genotypes[15]. Thus, it appears that neutrophil ADCC is not affected by the SIRPα genotype.

1.1. SIRPα Signaling

To investigate the mechanism of CD47-SIRPα signaling, the immunological synapse between target cells and neutrophils was investigated. It was already established that Mac-1 is essential for the formation of this synapse[18]. However, whether and how SIRPα signaling affects the formation or maintenance of the synapse was not yet clear. During the formation of effector-target interactions, CD47 and SIRPα are both present in the immunological synapse, as SIRPα translocates to the synapse in the presence of CD47, while it is excluded from the synapse in the absence of CD47[19][20]. Cell–cell contacts between neutrophils and CD47-expressing or CD47-deficient SKBR3 cells were analyzed and indicated that disruption of the CD47-SIRPα axis resulted in the promotion of neutrophil–tumor cell interactions in the presence of tumor-targeting antibodies[21].
After ligation by CD47, ITIM motifs in the cytoplasmic tail of SIRPα are phosphorylated, most likely by Src family kinases. This leads to recruitment of tyrosine phosphatases, in particular Src homology region 2 (SH2)-domain-containing phosphatase-1 (SHP-1) and -2 (SHP-2), which are considered to be principal mediators of SIRPα inhibitory signaling (Figure 1)[22][23]. After recruitment of SHP-1 and SHP-2 to SIRPα, these phosphates undergo conformational changes, allowing them to become activated[24]. The phosphatases can subsequently dephosphorylate various downstream substrates, thereby regulating pivotal intracellular signaling pathways, such as FcR and TLR signaling[21][25][26]. Therefore, different effector functions can be regulated by inhibitory signaling through CD47-SIRPα interactions. In addition, SIRPα might associate with the inhibitory protein kinase Csk and the adaptor protein Grb-2[27], but the role of these molecules in neutrophil killing has not been explored.
A similar mechanism might affect effector functions of other SIRPα-expressing cells, such as ADCP by macrophages. The interaction of CD47 with SIRPα on macrophages led to suppressed integrin activation and reduced the spreading and engulfment of mAb-opsonized beads[19]. In addition to myeloid cells, SIRPα is also expressed on B1 lymphocytes, a subtype of murine B cells, which produce natural antibodies[28]. Using transgenic mice which lack the intracellular domain of SIRPα and therefore have defective SIRPα signaling, it was observed that B1 cells produce more antibodies when SIRPα signaling is disrupted. In addition, these SIRPα-mutant B1 cells displayed enhanced Mac-1 integrin-dependent migration[28]. Taken together, these studies demonstrate that blocking SIRPα can enhance various Mac-1 integrin-dependent cellular functions, including cytotoxicity and migration, and suggest that the function of the CD47-SIRPα checkpoint may be intimately linked to that of Mac-1.

1.2. Neutrophil Effector Functions Influenced by CD47-SIRPα

Neutrophils have various effector functions essential for their role in immunity. As SIRPα signaling can regulate various signaling pathways, different effector functions may be influenced by the CD47-SIRPα interaction. In the 1990s, it was suggested that CD47 may play a role in neutrophil transmigration[29][30][31]. More recently, signaling via the CD47-SIRPα axis has been demonstrated to regulate neutrophil-mediated cytotoxicity[32].
Anti-CD47 mAbs did not disrupt neutrophil adhesion to epithelial cells, indicating that CD47 may affect the transmigration step of neutrophils across the epithelial layer[30]. This effect was mediated by tyrosine kinases, such as Src family kinases and Syk tyrosine kinases, as specific inhibition reverted the effect of anti-CD47 mAbs[33][34]. In vivo studies with CD47-deficient mice suggested a prominent defect in neutrophil extravasation leading to a lethal defect in the clearance of pathogenic bacteria. While this defect in neutrophil migration was clearly linked to β3-integrin function, it is not known whether CD47 was primarily required for pathogen recognition by neutrophils or for the actual migration process itself[31]. CD47 has a variety of well-established binding partners, including integrins, TSP-1, VEGFR and SIRPs. Therefore, it was investigated as to what extend CD47-SIRPα interactions are regulating trans-endothelial/epithelial migration. Anti-SIRP mAbs inhibited neutrophil transmigration across an epithelial monolayer and collagen-coated filters, albeit with different kinetics when compared to anti-CD47 mAbs[35]. Blocking the CD47-SIRPα interaction with a function-blocking peptide, which binds to the CD47 binding domain of SIRPα, resulted in inhibited neutrophil transepithelial migration in vitro[36]. Of note, questions with respect to the specificity of the peptide for CD47-SIRPα interactions can be raised. However, SIRPα-mutant mouse neutrophils, lacking the cytoplasmic region of SIRPα, transmigrated significantly less in vitro when compared to wild type (WT) neutrophils in response to the chemoattractant C5a[37]. In vivo, transmigration of these SIRPα-mutant neutrophils was also slightly delayed when compared to WT neutrophils[37]. This demonstrates that signaling via the intracellular tail of SIRPα may, at least to some extent, controls neutrophil transmigration. Nonetheless, it remains difficult to anticipate how much of an effect SIRPα signaling may have on the overall accumulation of neutrophils in tissues, including tumors, even though such migration may be clearly affected by CD47-targeting agents.
In addition to an effect on neutrophil transmigration, the CD47-SIRPα axis also regulates neutrophil cytotoxicity. Pioneering studies reported by Oldenborg et al. showed that CD47 restricted the clearing of red blood cells (RBC), suggesting that the broadly expressed CD47 functions as a signal of ‘self’ to control the elimination of normal cells by the immune system[38]. In particular, it was found that CD47-deficient RBCs were rapidly cleared, within hours, after their infusion into healthy recipient mice due to phagocytosis by macrophages[38]. For comparison, normal CD47-expressing RBC have a lifespan of 45 days in mice. Thus, it became clear that CD47 essentially functions as a ‘don’t eat me’ signal. It was established in subsequent studies that SIRPα was the inhibitory receptor limiting the phagocytosis of CD47-expressing erythrocytes and that CD47-SIRPα interactions were also restricting phagocytosis and clearance of IgG- or complement- opsonized erythrocytes[23][39]. It should be noted that not only macrophages but also neutrophils are able to eliminate IgG-opsonized RBCs, at least in vitro, and this process is also enhanced after blocking CD47-SIRPα[32]. This principle extends beyond red blood cells, and has now been observed for platelets and other hematopoietic cells, as well as non-hematopoietic cells[40][41][42][43][44][45]. In line with this, the lack of species compatibility between CD47-SIRPα is an important hurdle for xenotransplantation, and, inversely, an exaggerated binding of human CD47 to NOD SIRPα was found to be responsible for the superior engraftment of human tissues in immunodeficient mice in a NOD background[44][46][47]. These findings firmly established the role of the CD47-SIRPα axis in the clearance of normal cells, and also inspired the initial studies to demonstrate its role as an innate immune checkpoint in the antibody-dependent destruction of cancer cells by macrophages and neutrophils[17][48].

1.3. The Innate Immune Checkpoint CD47-SIRPα in Cancer

In the clinic, high CD47 expression has been correlated with a worse prognosis of patients with non-small cell lung cancer (NSCLC)[49]. Interactions between CD47 on tumor cells and SIRPα on neutrophils inhibit neutrophil effector functions, allowing the tumor to escape immune surveillance (Figure 2A)[48][50]. Therefore, targeting the innate immune checkpoint CD47-SIRPα could be a potential way to improve current antibody therapies, as it can stimulate neutrophil-mediated tumor killing (Figure 2B). Blocking CD47-SIRPα can be established by various methods: i.e., anti-CD47 mAbs, anti-SIRPα mAbs, or alternative ways, e.g., by downregulating CD47 or by affecting the SIRPα binding site. In vitro, macrophages can eliminate various opsonized solid[51][52][53][54][55][56][57] and hematological cancer[48][58][59][60] cell types via ADCP, which can be further promoted by treatment with anti-CD47 mAbs. Similarly, anti-CD47 mAbs enhance neutrophil-mediated ADCC of solid cancers in vitro, such as neuroblastoma[61]. However, it appears that neutrophils are less capable of killing hematologic cancer cells, and blockade of the CD47-SIRPα axis with anti-CD47 mAbs is not enough to promote tumor elimination. For example, neutrophils were unable to eliminate rituximab-opsonized B cell lymphoma cells[58]. Even when the CD47-SIRPα axis was disrupted using anti-CD47 Fab fragments, neutrophil-mediated ADCC was not improved, although tumor cell elimination was significantly increased when combined with sodium stibogluconate (SSG; an alleged inhibitor of SHP-1)[58]. It is important to note that some anti-CD47 antibodies can by themselves opsonize tumor cells, depending on their ability to still bind Fc-receptors, and hence act as a two-edged sword, i.e., by opsonizing tumor cells for phagocytosis and simultaneously inhibiting CD47-SIRPα interactions. In some cases, it therefore appears that anti-CD47 antibodies were sufficient for killing by myeloid cells, without the need of additional anti-TAA mAbs[53][59][62][63]. Since CD47 is broadly expressed on normal cells, it is highly undesirable to therapeutically use an anti-CD47 antibody with a functional Fc tail, as this would also trigger effector responses against the patient’s healthy cells. As an alternative to anti-CD47 antibodies, anti-SIRPα antibodies have also been studied for their ability to promote tumor elimination. By targeting SIRPα, neutrophil-mediated ADCC of various opsonized cancer cells, such as breast cancer[21], neuroblastoma[61], and colorectal adenocarcinoma[64][65] was promoted.
Figure 2. CD47-SIRPα signaling prevents neutrophil-mediated tumor cell killing. (A) Ligation of CD47 and SIRPα controls integrin (Mac-1) activation on neutrophils. This subsequently results in less cell–cell contacts between neutrophils and tumor cells, limiting trogoptosis of tumor cells. (B) Disruption of the CD47-SIRPα interaction allows Mac-1 activation, resulting in enhanced synapse formation, trogocytosis and eventually trogoptosis of antibody-opsonized cancer cells.
Blockade of the CD47-SIRPα axis generally only enhances tumor killing in the presence of tumor-targeting antibodies[15][58][17][61]. Consequently, not only enhanced CD47 expression on the tumor, but also decreased expression of TAAs on tumor cells can reduce or preclude neutrophil-mediated killing, as observed, e.g., in neuroblastoma cells of the mesenchymal phenotype that have lost GD2 expression[61].
Tumor-targeting mAbs stimulate neutrophil activation and tumor killing via FcR binding and signaling. As neutrophils express a variety of FcRs, different antibody isotypes can be used to stimulate neutrophils. Currently, most therapeutic mAbs are of the IgG1 isotype, which bind most FcγRs on neutrophils, including the highly expressed FcγRIIIb, which acts as a decoy receptor[66][67]. Treatment with IgG1 mAbs alone can enhance tumor killing by neutrophils. However, combination with CD47-SIRPα blockade significantly enhanced the cytotoxic capabilities of neutrophils[17]. In addition, some IgG2 mAbs are used in the clinic. IgG2 is able to effectively trigger myeloid cells, like neutrophils, at least as effective as IgG1, since it has a high affinity for FcγRIIa, which is the main FcγR involved in ADCC, and lower affinity for the decoy receptor FcγRIIIb[15][67][68]. 
Within bispecific antibodies (BsAb), opsonization and CD47-SIRPα blocking activity can be combined in one antibody, as Fab regions can target different antigens[69]. By combining a TAA-targeting mAb and anti-CD47 or anti-SIRPα mAb, immune cells can be recruited to the tumor and become fully activated by one antibody. For example, the GPC3xCD47 BsAb targets the TAA GPC3, expressed on hepatocellular carcinoma (HCC) cells, and CD47, as well as FcγRs via a functional IgG1 Fc tail[70]. Both in vitro and in vivo, GPC3xCD47 BsAb promoted neutrophil- and macrophage-mediated tumor killing of GPC3-expressing Raji cells. Similarly, the CD47xEGFR-IgG1 BsAb enhanced neutrophil ADCC of EGFR-expressing cancer cells[71]. The CD70/KWAR23 BsAb targets the TAA CD70 and SIRPα[65]. This BsAb significantly enhanced phagocytosis of CD70-expressing cancer cell lines in vitro. Furthermore, CD70/KWAR23 BsAbs limited the growth of Burkitt’s lymphoma cells in vivo[65]. These preclinical studies have demonstrated that blocking the CD47-SIRPα interaction, by either mAbs or BsAbs, may promote tumor cell killing by myeloid cells such as neutrophils and macrophages.

2. Targeting CD47-SIRPα to Potentiate Antibody Therapy

The preclinical evidence that inhibition of the CD47-SIRPα checkpoint may promote the efficacy of tumor-directed therapeutic antibodies has prompted the clinical development of a variety of compounds targeting CD47-SIRPα. Currently, different agents, such as antibodies against either CD47 or SIRPα, or other therapeutic biologics directed against CD47, are being investigated for their ability to block the CD47-SIRPα axis to promote tumor reduction. Whereas CD47-SIRPα targeting is often referred to as a method to improve macrophage mediated-phagocytosis, it is clear that neutrophils may also play a critical role as effector cells towards cancer cells during tumor-targeting antibody therapy in general[65][72][73][74][75]. Moreover, neutrophils may also prominently contribute to the enhanced tumor elimination after CD47-SIRPα disruption[65]. In addition, there is accumulating evidence that also adaptive T cell-mediated anti-cancer immunity can be promoted by CD47-SIRPα blockade[76][77]. Clearly, this also sets the stage for a combination of CD47-SIRPα antagonists with PD1–PDL1 inhibitors[78][79][80][81]. Along these lines, there is even initial evidence that CAR-T cell activity may be promoted by CD47-SIRPα inhibitors[82].

2.1. CD47-Targeting Agents

Many different CD47-targeting agents have been developed, of which various agents have entered the clinical stage. Magrolimab (also known as GS-4721 or Hu5F9-G4) is a humanized anti-CD47 blocking antibody with a IgG4 tail modified to prevent Fab arm exchange[83]. As the IgG tail is still functional, at least to some extent with respect to FcγRI binding[84], the anti-CD47 antibody may simultaneously function as an opsonizing antibody. In pre-clinical studies, combined treatment with Magrolimab and trastuzumab resulted in enhanced anti-tumor effects in NSG and C57BL/6 mice that had been xenografted with human SKBR3 cancer cells[85]. Treatment with Magrolimab or trastuzumab alone did not decrease tumor size in vivo. Due to these promising pre-clinical results, Magrolimab was the first in class anti-CD47 mAb that entered clinical trials, and is currently also the most clinically advanced CD47-SIRPα-targeting agent. Treatment with various doses of Magrolimab induced mainly grade I and II adverse events, including but not limited to transient anemia (57% of patients), lymphopenia (34%) and hyperbilirubinemia (34%). Moreover, partial remissions were observed in two patients with ovarian/fallopian tube cancers[86]. Currently, a large variety of clinical trials are ongoing to investigate the effect of Magrolimab for the treatment of various cancers.
Another anti-CD47 antibody is CC-90002, which has a humanized IgG4-PE (S228P and L235E mutation) tail, preventing FcγR interactions[87]. In pre-clinical studies, CC-90002 induced anti-tumor activity in vitro and in vivo against various hematological and solid cancers[88]. In a phase I trial (NCT02641002), patients with relapsed and/or refractory (r/r) AML and MDS were treated with CC-90002. Serious treatment-related adverse events were observed in 82% of patients and included febrile neutropenia (10/23) and bacteremia (4/23). In addition, no objective responses were observed in the treated patients. Due to the lack of a clinically sufficiently encouraging profile, as well as frequent anti-drug antibodies (ADA) development, this program was discontinued. CC-90002 treatment was also investigated as therapy for NHL patients in combination with rituximab (NCT02367196)[89], but this trial also showed low efficacy and was discontinued.
Letaplimab (also referred to as IBI188) is another anti-CD47 IgG4 antibody. Similar to the other anti-CD47 mAbs, Letaplimab was able to promote macrophage ADCP in vitro. In addition, it stimulated anti-tumor effects in NHL and AML/MDS xenograft mouse models in combination with rituximab or azacitidine[90]. In an initial phase Ia clinical trial (NCT03763149), the tolerability and safety of Letaplimab were assessed in patients with advanced or refractory solid tumors or lymphoma[91]. In general, treatment was well tolerated, with mainly grade I or II adverse events. Three out of twenty patients experienced adverse events of grade III or higher, i.e., hyperbilirubinemia, thrombocytopenia or anemia, each in one patient. Currently, five other clinical trials are ongoing with Leraplimab as a monotherapy, or in combination with rituximab, anti-PD-1, or chemotherapy in patients with various cancers, including solid tumors, lymphomas, MDS or AML.
Lemzoparlimab (also referred to as TJ011133 or TJC4) is also a fully human anti-CD47 IgG4 antibody. As most anti-CD47 antibodies cause anemia due to phagocytosis of RBCs, Lemzoparlimab was generated to specifically target CD47 on malignant cells while not recognizing CD47 on RBCs, due to unique CD47 binding properties[92]. In a phase I study (NCT03934814), patients with solid tumors were treated with monotherapy of Lemzoparlimab[92]. During this trial, only grade I or II adverse events were observed, including anemia in 30% of patients. In addition, one out of three patients treated with 30 mg/kg Lemzoparlimab had a partial response, and three out of sixteen patients in the trial achieved stable disease[92]. In the same trial, patients with r/r NHL were treated with a combination of Lemzoparlimab and rituximab[93]. Most adverse events were grade I and II, and anemia and thrombocytopenia were observed as one isolated episode. In addition, three out of seven patients had a CR, one had a partial response, and three achieved stable disease. In an ongoing phase I/II clinical trial (NCT04202003), r/r AML and MDS patients were treated with monotherapy of Lemzoparlimab[94]. Most adverse events were grade I or II, but one patient experienced grade III thrombocytopenia. As recruitment is still ongoing, no results are yet available on response rates in this trial.
Another method to target CD47 is with a fusion protein consisting of the N-terminal IgV-domain of SIRPα and a functional Fc region, also known as SIRPα-Fc. These proteins basically function as a decoy receptor and prevent CD47 binding to SIRPα. In addition, the functional Fc tail can interact with FcγRs, to further enhance anti-tumor activity through, e.g., ADCP or ADCC. An example of a SIRPα-Fc in clinical trials is TTI-621, a fully human SIRPα-Fc with a functional IgG1 Fc region[95]. In vitro, TTI-621 was able to strongly bind various tumor cell lines and primary patient tumors[95]. In addition, TTI-621 also bound to cells in peripheral blood, as CD47 is widely expressed on normal cells. In co-cultures, the addition of TTI-621 significantly enhanced macrophage phagocytosis of various hematologic and solid tumors[95][96]. The in vivo treatment of AML xenografted mice with TTI-621 resulted in significantly reduced tumor burden[95]. Similar results were observed with B cell lymphoma xenograft models. Treatment tolerance and adverse events were therefore assessed in phase I clinical trials (NCT02663518, NCT02890368), in which patients with relapsed or refractory hematologic or solid malignancies were treated with TTI-621 alone or in combination with rituximab or nivolumab (anti-PD-1, a checkpoint molecule on T cells)[97][98]. These initial trials demonstrated that treatment with TTI-621 does not cause severe toxicities (at the maximally tolerated dose) and has some anti-tumor effects in various cancer types.
TTI-622 also is a fully human SIRPα-Fc, consisting of the CD47-binding domain of SIRPα and an IgG4 Fc tail. It was suggested that TTI-622 does not bind to RBCs, unlike many anti-CD47 agents, thereby limiting adverse events such as anemia. In an ongoing phase I trial (NCT03530683), preliminary results were published of 25 patients with r/r lymphoma, who were treated with various doses of TTI-622 monotherapy[99]. In 48% of patients, treatment-related adverse events were reported, mostly being grade I or II. Grade III adverse events observed included neutropenia (9%), thrombocytopenia (5%) and anemia (2%). Objective responses were observed in nine patients, and included two CRs and seven PRs[100]. In this ongoing trial, combinations of TTI-622 with azacitidine or other chemotherapeutic agents are also being investigated in hematologic cancers. Moreover, a clinical trial (NCT05139225) has started in which the toxicity and efficacy of TTI-621 and TTI-622 are being compared in combination with the anti-CD38 antibody daratumumab in relapsing multiple myeloma patients.
ALX148 (also known as Evorpacept) is another SIRPα-Fc fusion protein. More specifically, ALX148 consists of an inactive human IgG1 Fc region that is fused to a modified N-terminal IgV-domain of SIRPα, which enhances CD47 binding[101][102]. As ALX148 has ~50,000× higher binding affinity to CD47 compared to wild-type SIRPα, it prevents SIRPα ligation by acting as a potent decoy receptor. The Fc region is able to interact with neonatal Fc receptors, allowing for extended pharmacokinetics. Contrarily, the Fc tail is unable to bind human FcγRs, preventing targeting of immune cells to normal cells[102]. In pre-clinical studies, ALX148 improved the phagocytosis of OE19, DLD-1, MM1.R, and Daudi tumor cells opsonized with trastuzumab, cetuximab, daratumumab (anti-CD38), and obinutuzumab (anti-CD20), respectively[102]. Mice engrafted with human B cell mantle cell lymphoma were treated with ALX148 or obinutuzumab alone or as combination therapy[102]. Combination treatment significantly inhibited tumor growth when compared to monotherapies. Similar results were observed in mice engrafted with OE19 gastroesophageal tumors, treated with ALX148 and trastuzumab, and mice harboring Raji B cell lymphoma tumors, treated with ALX148 and rituximab[102]. In a phase I clinical trial (NCT03013218; ASPEN-1), 110 patients with advanced or metastatic solid tumors were treated with various doses of ALX148 alone or in combination with pembrolizumab (anti-PD-1) or trastuzumab[103]. All treatments were well tolerated, with four serious adverse events in patients treated with ALX148 alone, five in patients treated with ALX148 and pembrolizumab, and one serious adverse event related to ALX148 plus trastuzumab treatment. The most common serious adverse events were thrombocytopenia and neutropenia. In addition to toxicity, the preliminary therapeutic effects of ALX148 were assessed. Of patients treated with monotherapy with ALX148 18% had stable disease. Currently, other clinical trials are ongoing in which ALX148 is being given in combination with various mAbs and chemotherapeutic agents to treat patients with hematologic or solid cancers.
Targeting CD47 on tumor cells allows for simultaneous tumor cell opsonization when the compounds contains a functional Fc tail. However, as indicated above, CD47 is widely expressed on virtually all cells in the body, and, particularly, hematologic adverse events are often observed in patients treated with anti-CD47 mAbs, e.g. anemia, thrombocytopenia, lymphopenia, and neutropenia. In addition, anti-CD47 antibodies may not only disrupt interactions with SIRPα, but also with other CD47 ligands, e.g., thrombosponin-1 or integrins, which could cause other adverse events[104]. Therefore, anti-SIRPα antibodies may in principle provide a better alternative.

2.2. Anti-SIRPα mAbs

Since SIRPα expression is much more restricted, with its expression largely confined to myeloid immune cells, it may be easier to saturate. Therefore, lower antibody concentrations may be needed to obtain beneficial clinical responses[104]. Nonetheless, an important aspect to consider is the large homology between SIRP family members. For example, SIRPγ also binds CD47, but is expressed on T cells, and has been suggested to play a role in T cell activation and transmigration in vitro[89]. Thus, the specificity of anti-SIRPα antibodies is key, and if such antibodies cross-react with other SIRP family members, their potential associated effects on safety and efficacy should be considered.
The first anti-SIRPα mAb entering clinical trials was CC-95251, a fully human IgG1 anti-SIRPα antibody with a K322A mutation, rendering the Fc tail inactive in terms of complement activation, but maintaining FcγR binding capacity[105]. In pre-clinical studies, CC-95251 demonstrated a synergistic effect with rituximab to promote phagocytosis of tumor cells by macrophages. In addition, intravenous administration appeared to be safe in cynomolgus monkeys, as no significant depletion of blood cell counts was observed[105]. Following these results, a phase 1 clinical trial (NCT03783403) was initiated, in which 230 patients with advanced solid or hematologic malignancies are intended to be treated with CC-95251 monotherapy or in combination with cetuximab or rituximab. Recently, the first interim results of 17 NHL patients treated with CC-95251 and rituximab were published[106]. In these patients, grade 3 or higher adverse events included neutropenia (53%), infections (24%) and thrombocytopenia (6%). The ORR was 56% and 25% of patients achieved a CR[106]. This trial is still ongoing, and recently another trial (NCT05168202) has been announced investigating the effect of CC-95251 in combination with azacitidine on r/r AML and MDS.
BI765063 (also referred to as OSE-172) is a humanized IgG4 anti-SIRPα antibody with S229P and L445P mutations, which only binds to one of the major SIRPα polymorphic variants (V1, also known as SIRPαBIT) present in the population. BI765063 is reported to be unable to bind SIRPγ, and thus should preserve T cell activation and migration[81]. In vivo, a murine variant of BI765063 promoted ADCC and ADCP of triple-negative breast cancer cells. In addition, anti-tumor effects were enhanced even further in combination with other checkpoint blockades, e.g., anti-PD-L1 antibodies. Analysis of the TME demonstrated that T lymphocytes accumulated in the tumor in mouse models[81]. BI765063 has entered an initial phase I clinical trial (NCT03990233), in which it is used to treat patients with advanced solid tumors as a monotherapy, or in combination with an anti-PD-1 antibody (BI754091). Preliminary results have been presented at ASCO and ESMO meetings. Fifty patients with solid cancer have received monotherapy BI765063[107]. No dose-limiting toxicities were observed and mostly grade I and II adverse events were reported. Only one patient experienced a grade III infusion-related reaction and none of the patients had anemia or thrombocytopenia as a result of the treatment. One patient showed durable PR, and had increased CD8 T-cell infiltration into the TME upon BI765063 treatment. After two weeks, an increased expression of PD-L1 was measured on the tumor[107]. Thus, combination with anti-PD-1 or anti-PD-L1 antibodies may further enhance clinical benefit.

2.3. Alternative Ways to Disrupt CD47-SIRPα Interactions

Besides CD47- or SIRPα-targeting antibodies, the CD47-SIRPα axis can be disrupted in alternative ways, for example by downregulating CD47. Galectin-9 (Gal-9) is a β-galactoside-binding galectin, and has been described for its role in cancer, as loss of Gal-9 is associated with tumor progression and metastasis[108]. However, recently it has been identified that Gal-9 also affects CD47 expression[109]. Associated with this finding, in co-cultures, treatment with Gal-9 significantly enhanced trogocytosis of FaDu cells by neutrophils, but not phagocytosis by macrophages. In addition to downregulation of CD47 on tumor cells, it was shown that the treatment of neutrophils with Gal-9 induced neutrophil activation, such as induced calcium flux, and degranulation, measured by upregulation of CD11b, CD18, CD11c, CD15, CD66b and CD63 on the cell’s surface. In co-cultures with FaDu or Caco2 cancer cell lines, neutrophils were able to kill significantly more tumor cells after Gal-9 treatment[109].
Recently, a small molecule, RRx-001, was identified as a tumor targeting agent, as it also downregulates CD47 on tumor cells[110]. RRx-001 activates the peroxisome proliferator-activated receptor gamma (PPAR-γ), which is a nuclear receptor transcription factor that inhibits Myc by heterodimerizing with retinoid X receptor. Inhibition of the transcription factor Myc subsequently results in downregulation of CD47[111]. RRx-001 treatment decreased both the expression of CD47 on A549 lung cancer cells, and SIRPα expression on monocytes and macrophages in vitro[112]. Consequently, enhanced phagocytosis of A549 lung cancer, or AU-565, MCF-7, and MDA-MDB-231 breast cancer cells was observed. Treatment of A549-bearing nude mice with RRx-001 resulted in a significant reduction of tumor growth[112]. A phase I trial (NCT01359982) with 25 patients with advanced soluble cancers showed that treatment with RRx-001 was well tolerated with no clinically significant toxicity[113]. In addition, 67% of patients had stable disease and 5% had a partial response. A phase II clinical trial (NCT02489903) showed that RRx-001 is also able to downregulate PD-L1 on small cell lung cancer cells[114]. Moreover, RRx-001 can have a direct anti-tumor effect through epigenetic modulation in multiple myeloma cells[115]. Currently, RRx-001 is tested in various clinical trials[116].
CD47-SIRPα interactions can also be disrupted by modulating enzymatic modifications of the SIRPα-binding domain in CD47. In a FACS-based haploid genetic screen, the gene encoding glutaminyl-peptide cyclotransferase-like (QPCTL, isoQC) was identified to significantly reduce the binding capabilities of SIRPα to CD47[111][117]. QPCTL is an enzymatic modifier, which adds pyroglutamate modifications to proteins. It has previously been demonstrated that CD47 contains an N-terminal pyroglutamate, which is involved in SIRPα binding[110]. Knockout of QPCTL decreased SIRPα binding in various human cell lines (HAP1, A375, A431, A549, DLD1, and RKO), while the overall expression of CD47 remained unaffected[111]. Similarly, treatment with small molecule inhibitors targeting QPCTL, i.e., SEN177 and PQ912, significantly reduced binding to SIRPα. In a co-culture of human macrophages and anti-CD20 treated Raji cells, the addition of SEN177 significantly increased phagocytosis[111]. Neutrophil-mediated ADCC of cetuximab-treated A431 cells or trastuzumab-treated Ba/F3 cells was significantly enhanced by treatment with SEN177 or knockout of QPCTL as well. These results were confirmed by other studies, showing that SEN177 treatment significantly enhanced ADCP by macrophages and neutrophil-mediated ADCC[118][119][120]. Another QPCTL inhibitor, luteolin, also abrogated the interaction between CD47 and SIRPα[121][122]. In addition, in co-cultures of H929 or DLD1 cancer cells with mouse bone-marrow-derived macrophages, phagocytosis was significantly improved after treatment with luteolin. To determine the effect in vivo, human FcαRI transgenic BALB/c mice were injected with 1:1 WT and QPCTL knockout Ba/F3 cells[111]. Mice were subsequently treated with anti-Her-2/neu IgA antibodies or PBS. Only in the IgA anti-HER-2/neu treated mice was profound killing of QPCTL knockout cells observed. In addition, an influx of neutrophils into the tumor was observed as a result of anti-HER-2/neu IgA treatment in combination with QPCTL knockout. The specific depletion of neutrophils with anti-Ly6G antibodies abrogated the treatment effect, demonstrating that neutrophils were the main effector cells eliminating QPCTL-deficient tumor cells[111]. These studies demonstrate that alternative ways of targeting the CD47-SIRPα axis may perhaps also have potential to promote tumor elimination. However, more pre-clinical and clinical studies are needed to demonstrate whether these compounds are well tolerated and effective in patients.
Despite the promising preliminary results observed in the various clinical trials targeting the CD47-SIRPα axis, it is important to consider the ways by which tumor cells may adopt resistance against these therapies. Since neutrophils, but also macrophages, require tumor opsonization with anti-TAA antibodies, loss of TAA expression will prevent tumor opsonization and thereby reduce killing by these immune cells. This has already been observed for neutroblastoma cells, where the TAA expression of GD2 can decrease during anti-GD2 mAb therapy[61]. Moreover, tumor cells may upregulate other (perhaps less well defined) checkpoint molecules to limit immune activation and tumor killing. Lastly, tumor cells could escape elimination by preventing immune cell infiltration, by creating an immunosuppressive microenvironment. Thus, although CD47-SIRPα appears to enhance tumor killing, the therapy is dependent on the opsonization of the tumor cells and possibly also the immunosuppressive state of the TME.

This entry is adapted from the peer-reviewed paper 10.3390/cancers14143366

References

  1. Ellen M. van Beek; Fiona Cochrane; A. Neil Barclay; Timo K. Van Den Berg; Signal Regulatory Proteins in the Immune System. The Journal of Immunology 2005, 175, 7781-7787, 10.4049/jimmunol.175.12.7781.
  2. S Adams; L J Van Der Laan; E Vernon-Wilson; C Renardel De Lavalette; E A Döpp; C D Dijkstra; D L Simmons; T K Van Den Berg; Signal-regulatory protein is selectively expressed by myeloid and neuronal cells.. The Journal of Immunology 1998, 161, 1853-59, .
  3. T Vandenberg; Jeffrey Yoder; G Litman; On the origins of adaptive immunity: innate immune receptors join the tale. Trends in Immunology 2004, 25, 11-16, 10.1016/j.it.2003.11.006.
  4. Deborah Hatherley; Karl Harlos; D. Cameron Dunlop; David I. Stuart; A. Neil Barclay; The Structure of the Macrophage Signal Regulatory Protein α (SIRPα) Inhibitory Receptor Reveals a Binding Face Reminiscent of That Used by T Cell Receptors. Journal of Biological Chemistry 2007, 282, 14567-14575, 10.1074/jbc.m611511200.
  5. M.I. Reinhold; F.P. Lindberg; D. Plas; S. Reynolds; M.G. Peters; E.J. Brown; In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). Journal of Cell Science 1995, 108, 3419-3425, 10.1242/jcs.108.11.3419.
  6. Eric J. Brown; Integrin-associated protein (CD47) and its ligands. Trends in Cell Biology 2001, 11, 130-135, 10.1016/s0962-8924(00)01906-1.
  7. E Brown; L Hooper; T Ho; H Gresham; Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins.. Journal of Cell Biology 1990, 111, 2785-2794, 10.1083/jcb.111.6.2785.
  8. I G Campbell; P S Freemont; W Foulkes; J Trowsdale; An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains.. Cancer Research 1992, 52, 5416-5420, .
  9. Per-Arne Oldenborg; CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease. ISRN Hematology 2013, 2013, 1-19, 10.1155/2013/614619.
  10. Peihua Jiang; Carl F. Lagenaur; Vinodh Narayanan; Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule. Journal of Biological Chemistry 1999, 274, 559-562, 10.1074/jbc.274.2.559.
  11. Martina Seiffert; Charles Cant; Zhengjun Chen; Irene Rappold; Wolfram Brugger; Lothar Kanz; Eric J. Brown; Axel Ullrich; Hans-Jörg Bühring; Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47. Blood 1999, 94, 3633-3643, 10.1182/blood.v94.11.3633.
  12. Elizabeth F. Vernon-Wilson; Wai-Jing Kee; Antony C. Willis; A. Neil Barclay; David L. Simmons; Marion H. Brown; CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1. European Journal of Immunology 2000, 30, 2130-2137, 10.1002/1521-4141(2000)30:8%3C2130::AID-IMMU2130%3E3.0.CO;2-8.
  13. Deborah Hatherley; Stephen Graham; Jessie Turner; Karl Harlos; David I. Stuart; A. Neil Barclay; Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47. Molecular Cell 2008, 31, 266-277, 10.1016/j.molcel.2008.05.026.
  14. Meike E. W. Logtenberg; J. H. Marco Jansen; Matthijs Raaben; Mireille Toebes; Katka Franke; Arianne M. Brandsma; Hanke L. Matlung; Astrid Fauster; Raquel Gomez-Eerland; Noor A. M. Bakker; et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nature Medicine 2019, 25, 612-619, 10.1038/s41591-019-0356-z.
  15. Louise W. Treffers; Xi Wen Zhao; Joris Van Der Heijden; Sietse Q. Nagelkerke; Dieke J. Van Rees; Patricia Gonzalez; Judy Geissler; Paul Verkuijlen; Michel Van Houdt; Martin De Boer; et al. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells. European Journal of Immunology 2017, 48, 344-354, 10.1002/eji.201747215.
  16. Deborah Hatherley; Susan Lea; Steven Johnson; A. Neil Barclay; Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47. Journal of Biological Chemistry 2014, 289, 10024-10028, 10.1074/jbc.m114.550558.
  17. Xi Wen Zhao; Ellen M. van Beek; Karin Schornagel; Hans Van der Maaden; Michel Van Houdt; Marielle A. Otten; Pascal Finetti; Marjolein Van Egmond; Takashi Matozaki; Georg Kraal; et al. CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proceedings of the National Academy of Sciences 2011, 108, 18342-18347, 10.1073/pnas.1106550108.
  18. Annemiek van Spriel; Jeanette Leusen; Marjolein Van Egmond; Henry B. P. M. Dijkman; Karel J. M. Assmann; Tanya N. Mayadas; Jan G. J. Van De Winkel; Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001, 97, 2478-2486, 10.1182/blood.v97.8.2478.
  19. Meghan A. Morrissey; Nadja Kern; Ronald D. Vale; CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis. Immunity 2020, 53, 290-302.e6, 10.1016/j.immuni.2020.07.008.
  20. Richard K. Tsai; Dennis E. Discher; Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. Journal of Cell Biology 2008, 180, 989-1003, 10.1083/jcb.200708043.
  21. Hanke L. Matlung; Liane Babes; Xi Wen Zhao; Michel van Houdt; Louise W. Treffers; Dieke J. van Rees; Katka Franke; Karin Schornagel; Paul Verkuijlen; Hans Janssen; et al. Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Reports 2018, 23, 3946-3959.e6, 10.1016/j.celrep.2018.05.082.
  22. Alexei Kharitonenkov; Zhengjun Chen; Irmi Sures; Hongyang Wang; James Schilling; Axel Ullrich; A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 1997, 386, 181-186, 10.1038/386181a0.
  23. Per-Arne Oldenborg; Hattie D. Gresham; Frederik P. Lindberg; Cd47-Signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis. Journal of Experimental Medicine 2001, 193, 855-862, 10.1084/jem.193.7.855.
  24. Ulrike Lorenz; SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunological Reviews 2009, 228, 342-359, 10.1111/j.1600-065x.2008.00760.x.
  25. Louise W. Treffers; Toine Ten Broeke; Thies Rösner; J. H. Marco Jansen; Michel van Houdt; Steffen Kahle; Karin Schornagel; Paul J.J.H. Verkuijlen; Jan M. Prins; Katka Franke; et al. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47–SIRPα Checkpoint Inhibition. Cancer Immunology Research 2020, 8, 120-130, 10.1158/2326-6066.cir-19-0144.
  26. Eun-Ju Kim; Kyoungho Suk; Won-Ha Lee; SHPS-1 and a synthetic peptide representing its ITIM inhibit the MyD88, but not TRIF, pathway of TLR signaling through activation of SHP and PI3K in THP-1 cells. Inflammation Research 2013, 62, 377-386, 10.1007/s00011-013-0589-0.
  27. André Veillette; Eric Thibaudeau; Sylvain Latour; High Expression of Inhibitory Receptor SHPS-1 and Its Association with Protein-tyrosine Phosphatase SHP-1 in Macrophages. Journal of Biological Chemistry 1998, 273, 22719-22728, 10.1074/jbc.273.35.22719.
  28. Katka Franke; Saravanan Y. Pillai; Mark Hoogenboezem; Marion J. J. Gijbels; Hanke L. Matlung; Judy Geissler; Hugo Olsman; Chantal Pottgens; Patrick J. Van Gorp; Maria Ozsvar-Kozma; et al. SIRPα on Mouse B1 Cells Restricts Lymphoid Tissue Migration and Natural Antibody Production. Frontiers in Immunology 2020, 11, 570963, 10.3389/fimmu.2020.570963.
  29. D Cooper; F P Lindberg; J R Gamble; E J Brown; M A Vadas; Transendothelial migration of neutrophils involves integrin-associated protein (CD47).. Proceedings of the National Academy of Sciences 1995, 92, 3978-3982, 10.1073/pnas.92.9.3978.
  30. C A Parkos; S P Colgan; T W Liang; A Nusrat; A E Bacarra; D K Carnes; J L Madara; CD47 mediates post-adhesive events required for neutrophil migration across polarized intestinal epithelia.. Journal of Cell Biology 1996, 132, 437-450, 10.1083/jcb.132.3.437.
  31. Frederik P. Lindberg; Daniel C. Bullard; Tony E. Caver; Hattie D. Gresham; Arthur L. Beaudet; Eric J. Brown; Decreased Resistance to Bacterial Infection and Granulocyte Defects in IAP-Deficient Mice. Science 1996, 274, 795-798, 10.1126/science.274.5288.795.
  32. Sanne M. Meinderts; Per-Arne Oldenborg; Boukje M. Beuger; Thomas R. L. Klei; Johanna Johansson; Taco W. Kuijpers; Takashi Matozaki; Elise J. Huisman; Masja de Haas; Timo K. Van Den Berg; et al. Human and murine splenic neutrophils are potent phagocytes of IgG-opsonized red blood cells. Blood Advances 2017, 1, 875-886, 10.1182/bloodadvances.2017004671.
  33. Yuan Liu; Didier Merlin; Stephanie L. Burst; Mildred Pochet; James L. Madara; Charles A. Parkos; The Role of CD47 in Neutrophil Transmigration. Journal of Biological Chemistry 2001, 276, 40156-40166, 10.1074/jbc.m104138200.
  34. Ke Zen; Yuan Liu; Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration. Immunobiology 2008, 213, 13-23, 10.1016/j.imbio.2007.07.001.
  35. Yuan Liu; Hans-Jörg Bühring; Ke Zen; Stephanie L. Burst; Frederick J. Schnell; Ifor R. Williams; Charles A. Parkos; Signal Regulatory Protein (SIRPα), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration. Journal of Biological Chemistry 2002, 277, 10028-10036, 10.1074/jbc.m109720200.
  36. Yuan Liu; Miriam B. O’Connor; Kenneth J. Mandell; Ke Zen; Axel Ullrich; Hans-Jörg Bühring; Charles A. Parkos; Peptide-Mediated Inhibition of Neutrophil Transmigration by Blocking CD47 Interactions with Signal Regulatory Protein α. The Journal of Immunology 2004, 172, 2578-2585, 10.4049/jimmunol.172.4.2578.
  37. Julian Alvarez-Zarate; Hanke L. Matlung; Takashi Matozaki; Taco W. Kuijpers; Isabelle Maridonneau-Parini; Timo K. Van Den Berg; Regulation of Phagocyte Migration by Signal Regulatory Protein-Alpha Signaling. PLOS ONE 2015, 10, e0127178, 10.1371/journal.pone.0127178.
  38. Per-Arne Oldenborg; Alex Zheleznyak; Yi-Fu Fang; Carl F. Lagenaur; Hattie D. Gresham; Frederik P. Lindberg; Role of CD47 as a Marker of Self on Red Blood Cells. Science 2000, 288, 2051-2054, 10.1126/science.288.5473.2051.
  39. Tomomi Ishikawa-Sekigami; Yoriaki Kaneko; Hideki Okazawa; Takeshi Tomizawa; Jun Okajo; Yasuyuki Saito; Chie Okuzawa; Minako Sugawara-Yokoo; Uichi Nishiyama; Hiroshi Ohnishi; et al. SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood 2006, 107, 341-348, 10.1182/blood-2005-05-1896.
  40. Mattias Olsson; Pierre Bruhns; William A. Frazier; Jeffrey V. Ravetch; Per-Arne Oldenborg; Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005, 105, 3577-3582, 10.1182/blood-2004-08-2980.
  41. Takuji Yamao; Tetsuya Noguchi; Osamu Takeuchi; Uichi Nishiyama; Haruhiko Morita; Tetsuya Hagiwara; Hironori Akahori; Takashi Kato; Kenjiro Inagaki; Hideki Okazawa; et al. Negative Regulation of Platelet Clearance and of the Macrophage Phagocytic Response by the Transmembrane Glycoprotein SHPS-1. Journal of Biological Chemistry 2002, 277, 39833-39839, 10.1074/jbc.m203287200.
  42. Bruce R. Blazar; Frederik P. Lindberg; Elizabeth Ingulli; Angela Panoskaltsis-Mortari; Per-Arne Oldenborg; Koho Iizuka; Wayne M. Yokoyama; Patricia A. Taylor; Cd47 (Integrin-Associated Protein) Engagement of Dendritic Cell and Macrophage Counterreceptors Is Required to Prevent the Clearance of Donor Lymphohematopoietic Cells. Journal of Experimental Medicine 2001, 194, 541-550, 10.1084/jem.194.4.541.
  43. Hui Wang; Maria Lucia Madariaga; Shumei Wang; Nico Van Rooijen; Per-Arne Oldenborg; Yong-Guang Yang; Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47 null cells. Proceedings of the National Academy of Sciences 2007, 104, 13744-13749, 10.1073/pnas.0702881104.
  44. Katsuto Takenaka; Tatiana K Prasolava; Jean Wang; Steven M Mortin-Toth; Sam Khalouei; Olga I Gan; John Dick; Jayne S Danska; Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nature Immunology 2007, 8, 1313-1323, 10.1038/ni1527.
  45. Timo K. Van Den Berg; C. Ellen van der Schoot; Innate immune ‘self’ recognition: a role for CD47–SIRPα interactions in hematopoietic stem cell transplantation. Trends in Immunology 2008, 29, 203-206, 10.1016/j.it.2008.02.004.
  46. Lai Shan Kwong; Marion H. Brown; A. Neil Barclay; Deborah Hatherley; Signal‐regulatory protein α from the NOD mouse binds human CD 47 with an exceptionally high affinity – implications for engraftment of human cells. Immunology 2014, 143, 61-67, 10.1111/imm.12290.
  47. Takuji Yamauchi; Katsuto Takenaka; Shingo Urata; Takahiro Shima; Yoshikane Kikushige; Takahito Tokuyama; Chika Iwamoto; Mariko Nishihara; Hiromi Iwasaki; Toshihiro Miyamoto; et al. Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood 2013, 121, 1316-1325, 10.1182/blood-2012-06-440354.
  48. Mark P. Chao; Ash A. Alizadeh; Chad Tang; June H. Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C. Cha; Charles K. Chan; Brent T. Tan; et al. Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. Cell 2010, 142, 699-713, 10.1016/j.cell.2010.07.044.
  49. Fangqiu Fu; Yang Zhang; Zhendong Gao; Yue Zhao; Zhexu Wen; Han Han; Yuan Li; Hong Hu; Haiquan Chen; Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 2021, 147, 739-747, 10.1007/s00432-020-03477-3.
  50. A. Neil Barclay; Timo K. Van Den Berg; The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target. Annual Review of Immunology 2014, 32, 25-50, 10.1146/annurev-immunol-032713-120142.
  51. Kipp Weiskopf; Nadine S. Jahchan; Peter Schnorr; Sandra Cristea; Aaron Ring; Roy L. Maute; Anne K. Volkmer; Jens-Peter Volkmer; Jie Liu; Jing Shan Lim; et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. Journal of Clinical Investigation 2016, 126, 2610-2620, 10.1172/jci81603.
  52. Feng Li; Bingke Lv; Yang Liu; Tian Hua; Jianbang Han; Chengmei Sun; Limin Xu; Zhongfei Zhang; Zhiming Feng; Yingqian Cai; et al. Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. OncoImmunology 2017, 7, e1391973, 10.1080/2162402x.2017.1391973.
  53. Stephen B. Willingham; Jens-Peter Volkmer; Andrew J. Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S. Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D. Cohen; et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences 2012, 109, 6662-6667, 10.1073/pnas.1121623109.
  54. Badreddin Edris; Kipp Weiskopf; Irving L Weissman; Matt van de Rijn; Flipping the script on macrophages in leiomyosarcoma. OncoImmunology 2012, 1, 1202-1204, 10.4161/onci.20799.
  55. Ji-Feng Xu; Xiao-Hong Pan; Shui-Jun Zhang; Chen Zhao; Bin-Song Qiu; Hai-Feng Gu; Jian-Fei Hong; Li Cao; Yu Chen; Bing Xia; et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget 2015, 6, 23662-23670, 10.18632/oncotarget.4282.
  56. Fei Liu; Miao Dai; Qinyang Xu; Xiaolu Zhu; Yang Zhou; Shuheng Jiang; Yahui Wang; Zhihong Ai; Li Ma; Yanli Zhang; et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. Oncogene 2018, 37, 2394-2409, 10.1038/s41388-017-0119-6.
  57. Mingzi Tan; Liancheng Zhu; Huiyu Zhuang; Yingying Hao; Song Gao; Shuice Liu; Qing Liu; Dawo Liu; Juanjuan Liu; Bei Lin; et al. Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis.. American journal of cancer research 2015, 5, 2777-87, .
  58. Dieke J. van Rees; Maximilian Brinkhaus; Bart Klein; Paul Verkuijlen; Anton T.J. Tool; Karin Schornagel; Louise W. Treffers; Michel van Houdt; Arnon P. Kater; Gestur Vidarsson; et al. Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing. Blood Advances 2022, 6, 2156-2166, 10.1182/bloodadvances.2021005367.
  59. Mark P. Chao; Chad Tang; Russell Pachynski; Robert Chin; Ravindra Majeti; Irving L. Weissman; Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011, 118, 4890-4901, 10.1182/blood-2011-02-338020.
  60. Mark P. Chao; Chris H. Takimoto; Dong Dong Feng; Kelly McKenna; Phung Gip; Jie Liu; Jens-Peter Volkmer; Irving L. Weissman; Ravindra Majeti; Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology 2020, 9, 1380, 10.3389/fonc.2019.01380.
  61. Paula Martínez-Sanz; Arjan J. Hoogendijk; Paul J. J. H. Verkuijlen; Karin Schornagel; Robin van Bruggen; Timo K. Van Den Berg; Godelieve A. M. Tytgat; Katka Franke; Taco W. Kuijpers; Hanke L. Matlung; et al. CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. Cancers 2021, 13, 4261, 10.3390/cancers13174261.
  62. Xi Wen Zhao; Taco W. Kuijpers; Timo K. Van Den Berg; Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?. Blood 2012, 119, 4333-4334, 10.1182/blood-2011-11-391367.
  63. Xi Wen Zhao; Hanke L. Matlung; Taco W. Kuijpers; Timo K. Van Den Berg; On the mechanism of CD47 targeting in cancer. Proceedings of the National Academy of Sciences 2012, 109, E2843-5, 10.1073/pnas.1209265109.
  64. Tracy C. Kuo; Amy Chen; Ons Harrabi; Jonathan T. Sockolosky; Anli Zhang; Emma Sangalang; Laura V. Doyle; Steven E. Kauder; Danielle Fontaine; Sangeetha Bollini; et al. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. Journal of Hematology & Oncology 2020, 13, 1-19, 10.1186/s13045-020-00989-w.
  65. Nan Guo Ring; Dietmar Herndler-Brandstetter; Kipp Weiskopf; Liang Shan; Jens-Peter Volkmer; Benson M. George; Melanie Lietzenmayer; Kelly M. McKenna; Tejaswitha J. Naik; Aaron McCarty; et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences 2017, 114, E10578-E10585, 10.1073/pnas.1710877114.
  66. Louise W. Treffers; Michel Van Houdt; Christine W. Bruggeman; Marieke H. Heineke; Xi Wen Zhao; Joris Van Der Heijden; Sietse Q. Nagelkerke; Paul J. J. H. Verkuijlen; Judy Geissler; Suzanne Lissenberg-Thunnissen; et al. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils. Frontiers in Immunology 2019, 9, 3124, 10.3389/fimmu.2018.03124.
  67. Gestur Vidarsson; Gillian Dekkers; Theo Rispens; IgG Subclasses and Allotypes: From Structure to Effector Functions. Frontiers in Immunology 2014, 5, 520-520, 10.3389/fimmu.2014.00520.
  68. Thies Rösner; Steffen Kahle; Francesca Montenegro; Hanke L. Matlung; J. H. Marco Jansen; Mitchell Evers; Frank Beurskens; Jeanette H.W. Leusen; Timo K. Van Den Berg; Thomas Valerius; et al. Immune Effector Functions of Human IgG2 Antibodies against EGFR. Molecular Cancer Therapeutics 2019, 18, 75-88, 10.1158/1535-7163.mct-18-0341.
  69. Sergey E Sedykh; Victor V Prinz; Valentina N Buneva; Georgy A Nevinsky; Bispecific antibodies: design, therapy, perspectives. Drug Design, Development and Therapy 2018, ume 12, 195-208, 10.2147/dddt.s151282.
  70. Kaixin Du; Yulu Li; Juan Liu; Wei Chen; Zhizhong Wei; Yong Luo; Huisi Liu; Yonghe Qi; Fengchao Wang; Jianhua Sui; et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Molecular Therapy 2021, 29, 1572-1584, 10.1016/j.ymthe.2021.01.006.
  71. Mark A. J. M. Hendriks; Emily M. Ploeg; Iris Koopmans; Isabel Britsch; Xiurong Ke; Douwe F. Samplonius; Wijnand Helfrich; Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. OncoImmunology 2020, 9, 1824323, 10.1080/2162402x.2020.1824323.
  72. Marcello Albanesi; David A. Mancardi; Friederike Jönsson; Bruno Iannascoli; Laurence Fiette; James Di Santo; Clifford A. Lowell; Pierre Bruhns; Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013, 122, 3160-3164, 10.1182/blood-2013-04-497446.
  73. Francisco J Hernandez-Ilizaliturri; Venkata Jupudy; Julie Ostberg; Ezogelin Oflazoglu; Amy Huberman; Elizabeth Repasky; Myron S Czuczman; Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.. Clinical Cancer Research 2003, 9, 5866-5873, .
  74. William M. Siders; Jacqueline Shields; Carrie Garron; Yanping Hu; Paula Boutin; Srinivas Shankara; William Weber; Bruce Roberts; Johanne M. Kaplan; Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leukemia & Lymphoma 2010, 51, 1293-1304, 10.3109/10428191003777963.
  75. Eric F. Zhu; Shuning A. Gai; Cary F. Opel; Byron H. Kwan; Rishi Surana; Martin C. Mihm; Monique J. Kauke; Kelly Moynihan; Alessandro Angelini; Robert Williams; et al. Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2. Cancer Cell 2015, 27, 489-501, 10.1016/j.ccell.2015.03.004.
  76. Diane Tseng; Jens-Peter Volkmer; Stephen B. Willingham; Humberto Contreras-Trujillo; John W. Fathman; Nathaniel B. Fernhoff; Jun Seita; Matthew A. Inlay; Kipp Weiskopf; Masanori Miyanishi; et al. Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences 2013, 110, 11103-11108, 10.1073/pnas.1305569110.
  77. Xiaojuan Liu; Yang Pu; Kyle R Cron; Liufu Deng; Justin Kline; William A. Frazier; Hairong Xu; Hua Peng; Yang-Xin Fu; Meng Michelle Xu; et al. CD47 blockade triggers T cell–mediated destruction of immunogenic tumors. Nature Medicine 2015, 21, 1209-1215, 10.1038/nm.3931.
  78. Tadahiko Yanagita; Yoji Murata; Daisuke Tanaka; Sei-Ichiro Motegi; Eri Arai; Edwin Widyanto Daniwijaya; Daisuke Hazama; Ken Washio; Yasuyuki Saito; Takenori Kotani; et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight 2017, 2, e89140, 10.1172/jci.insight.89140.
  79. Rodney Cheng-En Hsieh; Sunil Krishnan; Ren-Chin Wu; Akash R. Boda; Arthur Liu; Michelle Winkler; Wen-Hao Hsu; Steven Hsesheng Lin; Mien-Chie Hung; Li-Chuan Chan; et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Science Immunology 2022, 7, eabl9330, 10.1126/sciimmunol.abl9330.
  80. Jonathan T. Sockolosky; Michael Dougan; Jessica R. Ingram; Chia Chi M. Ho; Monique J. Kauke; Steven C. Almo; Hidde L. Ploegh; K. Christopher Garcia; Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences 2016, 113, E2646-E2654, 10.1073/pnas.1604268113.
  81. Vanessa Gauttier; Sabrina Pengam; Justine Durand; Kevin Biteau; Caroline Mary; Aurore Morello; Mélanie Néel; Georgia Porto; Géraldine Teppaz; Virginie Thepenier; et al. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. Journal of Clinical Investigation 2020, 130, 6109-6123, 10.1172/jci135528.
  82. Huanpeng Chen; Yuying Yang; Yuqing Deng; Fengjiao Wei; Qingyu Zhao; Yongqi Liu; Zhonghua Liu; Bolan Yu; Zhaofeng Huang; Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy. Journal for ImmunoTherapy of Cancer 2022, 10, e003737, 10.1136/jitc-2021-003737.
  83. Jie Liu; Lijuan Wang; Feifei Zhao; Serena Tseng; Cyndhavi Narayanan; Lei Shura; Stephen Willingham; Maureen Howard; Susan Prohaska; Jens Volkmer; et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLOS ONE 2015, 10, e0137345, 10.1371/journal.pone.0137345.
  84. Pierre Bruhns; Bruno Iannascoli; Patrick England; David A. Mancardi; Nadine Fernandez; Sylvie Jorieux; Marc Daëron; Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113, 3716-3725, 10.1182/blood-2008-09-179754.
  85. Rosalynd Upton; Allison Banuelos; Dongdong Feng; Tanuka Biswas; Kevin Kao; Kelly McKenna; Stephen Willingham; Po Yi Ho; Benyamin Rosental; Michal Caspi Tal; et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences 2021, 118, e2026849118, 10.1073/pnas.2026849118.
  86. Branimir I. Sikic; Nehal Lakhani; Amita Patnaik; Sumit A. Shah; Sreenivasa R. Chandana; Drew Rasco; A. Dimitrios Colevas; Timothy O’Rourke; Sujata Narayanan; Kyriakos Papadopoulos; et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology 2019, 37, 946-953, 10.1200/jco.18.02018.
  87. Amer M. Zeidan; Daniel J. DeAngelo; Jeanne Palmer; Christopher S. Seet; Martin S. Tallman; Xin Wei; Heather Raymon; Priya Sriraman; Stephan Kopytek; Jan Philipp Bewersdorf; et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals of Hematology 2022, 101, 557-569, 10.1007/s00277-021-04734-2.
  88. Rama Krishna Narla; Hardik Modi; Lilly Wong; Mahan Abassian; Daniel Bauer; Pragnya Desai; Bonny Gaffney; Pilgrim Jackson; Jim Leisten; Jing Liu; et al. Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo. Cancer Research 2017, 77, 4694-4694, 10.1158/1538-7445.am2017-4694.
  89. Pau Abrisqueta; Juan-Manuel Sancho; Raul Cordoba; Daniel O. Persky; Msce Charalambos Andreadis; Mph Scott F. Huntington; Cecilia Carpio; Daniel Morillo Giles; Xin Wei; Ying Fei Li; et al. Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood 2019, 134, 4089-4089, 10.1182/blood-2019-125310.
  90. Haiqing Ni; Lei Cao; Zhihai Wu; Li Wang; Shuaixiang Zhou; Xiaoli Guo; Yarong Gao; Hua Jing; Min Wu; Yang Liu; et al. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody. Cancer Immunology, Immunotherapy 2021, 71, 353-363, 10.1007/s00262-021-02989-2.
  91. Nehal Lakhani; Marlana Orloff; Siqing Fu; Ying Liu; Yan Wang; Hui Zhou; Kedan Lin; Fang Liu; Shuling Yan; Amita Patnaik; et al. 295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas. Regular and young investigator award abstracts 2020, 8, A180, 10.1136/jitc-2020-sitc2020.0295.
  92. Jordan Berlin; Wael Harb; Alex Adjei; Yan Xing; Paul Swiecicki; Mahesh Seetharam; Lakshminarayanan Nandagopal; Ajay Gopal; Cong Xu; Yuan Meng; et al. 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results. Regular and young investigator award abstracts 2020, 8, A233-A234, 10.1136/jitc-2020-sitc2020.0385.
  93. AmitKumar Mehta; Wael Harb; Claire Xu; Yuan Meng; Linda Lee; Vivian Yuan; Zhengyi Wang; Pengfei Song; Joan Huaqiong Shen; Ajay K Gopal; et al. Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results. Blood 2021, 138, 3542-3542, 10.1182/blood-2021-150606.
  94. Junyuan Qi; Jian Li; Bin Bin Jiang; Bo Jiang; Hongzhong Liu; Xinxin Cao; Meixiang Zhang; Yuan Meng; Xiaoyu Ma; Yingmin Jia; et al. A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results. Blood 2020, 136, 30-31, 10.1182/blood-2020-134391.
  95. Penka S. Petrova; Natasja Nielsen Viller; Mark Wong; Xinli Pang; Gloria H. Y. Lin; Karen Dodge; Vien Chai; Hui Chen; Vivian Lee; Violetta House; et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clinical Cancer Research 2017, 23, 1068-1079, 10.1158/1078-0432.ccr-16-1700.
  96. Gloria H. Y. Lin; Vien Chai; Vivian Lee; Karen Dodge; Tran Truong; Mark Wong; Lisa Johnson; Emma Linderoth; Xinli Pang; Jeff Winston; et al. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PLOS ONE 2017, 12, e0187262, 10.1371/journal.pone.0187262.
  97. Stephen M. Ansell; Michael B. Maris; Alexander M. Lesokhin; Robert W. Chen; Ian W. Flinn; Ahmed Sawas; Mark D. Minden; Diego Villa; Mary-Elizabeth M. Percival; Anjali S. Advani; et al. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clinical Cancer Research 2021, 27, 2190-2199, 10.1158/1078-0432.ccr-20-3706.
  98. Christiane Querfeld; John A Thompson; Matthew H Taylor; Jennifer A DeSimone; Jasmine M Zain; Andrei R Shustov; Carolyn Johns; Sue McCann; Gloria H Y Lin; Penka S Petrova; et al. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. The Lancet Haematology 2021, 8, e808-e817, 10.1016/s2352-3026(21)00271-4.
  99. Krish Patel; Radhakrishnan Ramchandren; Michael Maris; Alexander M. Lesokhin; Gottfried R. Von Keudell; Bruce D. Cheson; Jeff Zonder; Erlene K. Seymour; Tina Catalano; Gloria H. Y. Lin; et al. Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood 2020, 136, 46-47, 10.1182/blood-2020-136607.
  100. Krish Patel; Jeffrey A. Zonder; Dahlia Sano; Michael Maris; Alexander Lesokhin; Gottfried von Keudell; Catherine Lai; Rod Ramchandren; Tina Catalano; Gloria H. Y. Lin; et al. CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Blood 2021, 138, 3560-3560, 10.1182/blood-2021-153683.
  101. Kipp Weiskopf; Aaron M. Ring; Chia Chi M. Ho; Jens-Peter Volkmer; Aron M. Levin; Anne Kathrin Volkmer; Engin Özkan; Nathaniel B. Fernhoff; Matt van de Rijn; Irving L. Weissman; et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science 2013, 341, 88-91, 10.1126/science.1238856.
  102. Steven E. Kauder; Tracy C. Kuo; Ons Harrabi; Amy Chen; Emma Sangalang; Laura Doyle; Sony S. Rocha; Sangeetha Bollini; Bora Han; Janet Sim; et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLOS ONE 2018, 13, e0201832, 10.1371/journal.pone.0201832.
  103. Nehal J Lakhani; Laura Q M Chow; Justin F Gainor; Patricia LoRusso; Keun-Wook Lee; Hyun Cheol Chung; Jeeyun Lee; Yung-Jue Bang; Frank Stephen Hodi; Won Seog Kim; et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. The Lancet Oncology 2021, 22, 1740-1751, 10.1016/s1470-2045(21)00584-2.
  104. Timo K. Van Den Berg; Thomas Valerius; Myeloid immune-checkpoint inhibition enters the clinical stage. Nature Reviews Clinical Oncology 2018, 16, 275-276, 10.1038/s41571-018-0155-3.
  105. Henry Chan; Christina Trout; David Mikolon; Preston Adams; Roberto Guzman; Gustavo Fenalti; Konstantinos Mavrommatis; Mahan Abbasian; Lawrence Dearth; Brian Fox; et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood 2021, 138, 2271-2271, 10.1182/blood-2021-147262.
  106. Paolo Strati; Eliza Hawkes; Nilanjan Ghosh; Joseph M. Tuscano; Quincy Chu; Mary Ann Anderson; Amar Patel; Michael R. Burgess; Kristen Hege; Sapna Chhagan; et al. Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood 2021, 138, 2493-2493, 10.1182/blood-2021-147292.
  107. Stéphane Champiat; Philippe A. Cassier; Nuria Kotecki; Iphigenie Korakis; Armelle Vinceneux; Christiane Jungels; Jon Blatchford; Mabrouk M. Elgadi; Nicole Clarke; Claudia Fromond; et al. Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.. Journal of Clinical Oncology 2021, 39, 2623-2623, 10.1200/jco.2021.39.15_suppl.2623.
  108. Akemi Irie; Akira Yamauchi; Keiichi Kontani; Minoru Kihara; Dage Liu; Yukako Shirato; Masako Seki; Nozomu Nishi; Takanori Nakamura; Hiroyasu Yokomise; et al. Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast Cancer. Clinical Cancer Research 2005, 11, 2962-2968, 10.1158/1078-0432.ccr-04-0861.
  109. Natasha Ustyanovska Avtenyuk; Ghizlane Choukrani; Emanuele Ammatuna; Toshiro Niki; Ewa Cendrowicz; Harm Jan Lourens; Gerwin Huls; Valerie R. Wiersma; Edwin Bremer; Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity. Biomedicines 2021, 10, 66, 10.3390/biomedicines10010066.
  110. Bryan Oronsky; Xiaoning Guo; Xiaohui Wang; Pedro Cabrales; David Sher; Lou Cannizzo; Bob Wardle; Nacer Abrouk; Michelle Lybeck; Scott Caroen; et al. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development. Journal of Medicinal Chemistry 2021, 64, 7261-7271, 10.1021/acs.jmedchem.1c00599.
  111. Bryan Oronsky; Pedro Cabrales; Scott Caroen; Xiaoning Guo; Curtis Scribner; Arnold Oronsky; Tony R. Reid; RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia. Expert Opinion on Drug Metabolism & Toxicology 2021, 17, 355-357, 10.1080/17425255.2021.1876025.
  112. Pedro Cabrales; RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. Translational Oncology 2019, 12, 626-632, 10.1016/j.tranon.2018.12.001.
  113. Tony Reid; Bryan Oronsky; Jan Scicinski; Curt L Scribner; Susan J Knox; Shoucheng Ning; Donna M Peehl; Ron Korn; Meaghan Stirn; Corey A Carter; et al. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. The Lancet Oncology 2015, 16, 1133-1142, 10.1016/s1470-2045(15)00089-3.
  114. Yusuke Tomita; Bryan Oronsky; Nacer Abrouk; Pedro Cabrales; Tony R. Reid; Min-Jung Lee; Akira Yuno; Jonathan Baker; Sunmin Lee; Jane B. Trepel; et al. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit. Translational Lung Cancer Research 2021, 10, 274-278, 10.21037/tlcr-20-359.
  115. Deepika Sharma Das; Arghya Ray; Abhishek Das; Yan Song; Z Tian; Bryan Oronsky; Paul Richardson; Jan Scicinski; Dharminder Chauhan; Kenneth C. Anderson; et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia 2016, 30, 2187-2197, 10.1038/leu.2016.96.
  116. Bryan Oronsky; Tony R Reid; Christopher Larson; Scott Caroen; Mary Quinn; Erica Burbano; Gina Varner; Bennett Thilagar; Bradley Brown; Angelique Coyle; et al. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncology 2019, 15, 3427-3433, 10.2217/fon-2019-0317.
  117. Zhiqiang Wu; Linjun Weng; Tengbo Zhang; Hongling Tian; Lan Fang; Hongqi Teng; Wen Zhang; Jing Gao; Yun Hao; Yaxu Li; et al. Identification of Glutaminyl Cyclase isoenzyme isoQC as a regulator of SIRPα-CD47 axis. Cell Research 2019, 29, 502-505, 10.1038/s41422-019-0177-0.
  118. Niklas Baumann; Thies Rösner; J. H. Marco Jansen; Chilam Chan; Klara Marie Eichholz; Katja Klausz; Dorothee Winterberg; Kristina Müller; Andreas Humpe; Renate Burger; et al. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. Cancer Science 2021, 112, 3029-3040, 10.1111/cas.14999.
  119. Teresa L. Burgess; Joshua D. Amason; Jeffrey S. Rubin; Damien Y. Duveau; Laurence Lamy; David D. Roberts; Catherine L. Farrell; James Inglese; Craig J. Thomas; Thomas W. Miller; et al. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. PLOS ONE 2020, 15, e0226661, 10.1371/journal.pone.0226661.
  120. Mitchell Evers; Thies Rösner; Anna Duenkel; J. H. Marco Marco Jansen; Niklas Baumann; Toine Ten Broeke; Maaike Nederend; Klara Eichholz; Katja Klausz; Karli Reiding; et al. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. Blood Advances 2021, 5, 3807-3820, 10.1182/bloodadvances.2021004598.
  121. Zhiqiang Li; Xuemei Gu; Danni Rao; Meiling Lu; Jing Wen; Xinyan Chen; Hongbing Wang; Xianghuan Cui; Wenwen Tang; Shilin Xu; et al. Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation. Translational Oncology 2021, 14, 101129, 10.1016/j.tranon.2021.101129.
  122. Paolo Strati; Eliza Hawkes; Nilanjan Ghosh; Joseph M. Tuscano; Quincy Chu; Mary Ann Anderson; Amar Patel; Michael R. Burgess; Kristen Hege; Sapna Chhagan; et al. Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood 2021, 138, 2493-2493, 10.1182/blood-2021-147292.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback